A Regulatory Perspective on Manufacturing Processes Pertaining to Lyophilized Injectable Products
Related Experiment Video
Updated: Dec 13, 2025

Author Spotlight: Process Development for the Spray-Drying of Probiotic Bacteria and Evaluation of the Product Quality
Published on: April 7, 2023
Steve Y Rhieu1, David D Anderson2, Kumar Janoria2
1Office of Pharmaceutical Manufacturing Assessment, Office of Pharmaceutical Quality, Center of Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, 20993, USA. steve.rhieu@fda.hhs.gov.
Abstract:
Freeze-drying, also known as lyophilization, is a dehydration process designed to prolong the shelf life of injectable drug products. Here, we provide regulatory considerations for manufacturing processes specific to lyophilized injectable products. Specifically, a general discussion on each unit operation, including compounding, filtration, filling, and lyophilization, is provided to help the pharmaceutical industry establish reliable manufacturing processes from a regulatory perspective. In addition, a list of manufacturing-related deficiencies identified from a total of 263 new drug applications (NDAs) and abbreviated new drug applications (ANDAs) submitted for lyophilized injectable products is provided. We hope that the information presented in this report may help applicants avoid some common manufacturing-related deficiencies in regulatory submissions, thereby making high-quality lyophilized pharmaceuticals expeditiously available to the American public.
Related Concept Videos
Factors Influencing Drug Absorption: Pharmaceutical Parameters
Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules
Biopharmaceutical Factors Influencing Drug Product Design: Overview
Drug Regulation
Drug Products: Biologics, Biosimilars and Interchangeables
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

